Lower Hepatic Fat Is Associated With Improved Insulin Secretion in a High-Risk Prediabetes Subphenotype During Lifestyle Intervention.

"Duality of Interest. R.W. reports lecture fees from Novo Nordisk and Sanofi and travel grants from Eli Lilly. R.W. served on the advisory board of Akcea Therapeutics, Daiichi Sankyo, Sanofi, and Novo Nordisk. A.L.B. reports lecture fees and advisory board membership from AstraZeneca, Boehringer Ingelheim, and Novo Nordisk. A.F. reports lecture fees and advisory board membership from Sanofi, Novo Nordisk, Eli Lilly, and AstraZeneca. M.H. reports research grants from Boehringer Ingelheim and Sanofi (both to the University Hospital of Tübingen) and lecture fees from Sanofi, Novo Nordisk, Eli Lilly, and Merck Sharp & Dohme. M.F.W. is a scientific consultant for Housey Pharmaceutical Research Laboratories. No other potential conflicts of interest relevant to this article were reported."

"Funding. The study was supported by the German Center for Diabetes Research (DZD). The DZD is funded by the Bundesministerium für Bildung und Forschung (German Federal Ministry for Education and Research) and the states where its partner institutions are located (01GI0925). Additional support was received from the state of Baden-Württemberg to R.W. and A.F. (325400/58/2, Forum Gesundheitsstandort Baden-Württemberg)."